Repatha Cost in Louisiana 2026: Price, Coverage, and Savings Options

What Does Repatha Actually Cost in Louisiana in 2026?

Brand-name Repatha carries a Amgen list price of roughly $580 per month in Louisiana pharmacies in 2026, regardless of whether you pay cash or run it through insurance. That figure applies at major retail chains including Walgreens, CVS, and Walmart locations across the state. Without a coupon, copay card, or insurer negotiation, most Louisiana patients paying cash face the full amount.

The FDA approved evolocumab in August 2015 under the brand Repatha for two indications: adults with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy, and adults or adolescents aged 13 and older with heterozygous familial hypercholesterolemia (HeFH). [1] A separate indication covers homozygous familial hypercholesterolemia (HoFH) in patients aged 13 and older. [1]

Evolocumab works by binding to and inhibiting PCSK9, a protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more LDL receptors available, which pulls LDL-C out of the bloodstream. [2] The FOURIER trial (N=27,564) demonstrated a 59% reduction in LDL-C from baseline at 48 weeks (median) compared with placebo, and a 15% relative reduction in the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization (HR 0.85 to 95% CI 0.79-0.92, P<0.001). [3]

The monthly cost breakdown for Louisiana patients in 2026 looks like this:

• Cash price (brand Repatha): approximately $580/month
• With Amgen copay card (commercial insurance): as low as $0/month for eligible patients
• Louisiana Medicaid: not covered for most patients
• Compounded evolocumab (licensed 503A pharmacy): cost varies; may be substantially lower than brand pricing

Does Louisiana Medicaid Cover Repatha?

Louisiana Medicaid does not cover Repatha (evolocumab) for the majority of enrollees under its current 2026 formulary, including patients with familial hypercholesterolemia or established ASCVD. This is a common pattern across state Medicaid programs, where PCSK9 inhibitors have faced persistent coverage restrictions due to their high list price. [4]

Medicaid fee-for-service (FFS) programs in many states require prior authorization with strict step-therapy requirements. Louisiana's Medicaid managed care organizations (MCOs), including Aetna Better Health of Louisiana, AmeriHealth Caritas, Healthy Blue, Humana Healthy Horizons, and UnitedHealthcare Community Plan, each maintain their own drug formularies. These plans may impose more restrictive policies than federal baseline requirements. [5]

The Centers for Medicare and Medicaid Services (CMS) noted in its 2023 guidance that states must cover drugs when a manufacturer participates in the Medicaid Drug Rebate Program, but states retain the authority to impose prior authorization and step-therapy requirements that effectively limit access. [5] Evolocumab's manufacturer Amgen participates in that rebate program, yet Louisiana's MCOs have generally maintained non-coverage or highly restrictive prior authorization pathways that most patients do not pass.

Patients on Louisiana Medicaid who believe they meet clinical criteria should request a prior authorization with documentation of:

1. A baseline LDL-C above the plan's threshold (often 70 mg/dL or 100 mg/dL depending on the plan)
2. Maximum tolerated statin therapy for at least 90 days
3. An ASCVD event within the prior 12 months, or a confirmed FH diagnosis using Dutch Lipid Clinic Network criteria or genetic testing

If the initial prior authorization is denied, a physician-led appeal citing the 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction may improve the outcome. The ACC/AHA guidelines state: "For patients with clinical ASCVD who are at very high risk and have LDL-C ≥70 mg/dL on maximally tolerated statin plus ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor." [6]

Which Private Insurance Plans in Louisiana Cover Repatha?

Commercial insurers operating in Louisiana, including Blue Cross Blue Shield of Louisiana, Humana, Aetna, Cigna, and UnitedHealthcare, generally do cover evolocumab but place it on Tier 5 (specialty) with strict prior authorization requirements. [7] The prior authorization criteria across most commercial plans share a common structure.

Typical Louisiana commercial plan PA criteria for Repatha include:

• Documented ASCVD (prior MI, stroke, or peripheral artery disease) OR confirmed familial hypercholesterolemia
• LDL-C above a defined threshold despite maximally tolerated statin (often defined as rosuvastatin 40 mg or atorvastatin 80 mg for at least 8-12 weeks)
• Ezetimibe trial of at least 8 weeks in patients without a documented contraindication
• Prescriber attestation by a cardiologist or endocrinologist (some plans accept internal medicine or family medicine with chart documentation)

Blue Cross Blue Shield of Louisiana follows a specialty tier structure where evolocumab carries a 30-40% coinsurance after the deductible. [7] For a $580 list price, that translates to $174-$232 per month out-of-pocket even after insurance approval, before the Amgen savings card applies.

Medicare Part D plans in Louisiana cover evolocumab, though tier placement varies. Under Medicare Part D, enrollees in the catastrophic coverage phase pay 5% coinsurance, which on a $580/month drug equals approximately $29/month. Patients not yet in catastrophic coverage may face significantly higher costs depending on their plan's tier structure and deductible status. [8]

How Does the Amgen Repatha Savings Card Work in Louisiana?

The Amgen Repatha copay card reduces out-of-pocket costs to as low as $0 per month for commercially insured patients who qualify. The card covers up to $3,600 per calendar year in copays, deductibles, and coinsurance. [9]

Eligibility rules that Louisiana patients must meet:

• Must have commercial (private) insurance; the card explicitly cannot be used by patients enrolled in Medicare, Medicaid, or any federal or state government program
• Must be a U.S. resident (Louisiana residents qualify)
• Prescription must be for an FDA-approved indication

Enrollment takes place online at repatha.com or by calling 1-844-REPATHA. The card is accepted at most Louisiana retail and specialty pharmacies. Patients using specialty pharmacy distribution through Accredo or CVS Specialty may need to confirm card eligibility at enrollment. [9]

For patients who do not qualify for the copay card (primarily Medicare and Medicaid enrollees), Amgen offers the Amgen Safety Net Foundation program, which provides free medication to patients with household income at or below 500% of the federal poverty level who lack adequate insurance coverage. [10] In 2025 to 500% FPL for a single person equaled approximately $75,300/year. Louisiana's median household income of approximately $54,000 means a substantial portion of uninsured or underinsured Louisiana patients may qualify. [10]

Is Compounded Evolocumab Legal in Louisiana?

Compounded evolocumab from a licensed 503A pharmacy is legal in Louisiana, and several compounding pharmacies licensed in the state have begun offering it. This option has attracted attention from patients who cannot afford brand Repatha and do not qualify for the Amgen savings card. [11]

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug product for an identified individual patient based on a valid prescription from a licensed prescriber. [11] Louisiana Board of Pharmacy regulations require that 503A compounding pharmacies operate under a valid state license and comply with USP <797> sterile compounding standards when preparing injectable compounds such as evolocumab, which is administered subcutaneously. [12]

The FDA's position on compounded copies of approved drugs is relevant here. The agency has stated that compounding a drug that is essentially a copy of a commercially available product "raises concerns" under 503A, and FDA guidance from 2023 clarified that pharmacies should not compound products that are "essentially a copy" solely to offer a lower-cost alternative. [11] However, a prescriber can document a clinical difference, such as a patient's allergy to an excipient in brand Repatha or a specific concentration requirement, to support the medical necessity of a compounded preparation.

Clinicians prescribing compounded evolocumab in Louisiana should document:

1. The specific clinical rationale distinguishing the compounded preparation from the FDA-approved product
2. The patient's inability to access the FDA-approved product due to cost or supply
3. The pharmacy's USP <797> compliance status
4. Patient counseling on the differences between compounded and FDA-approved evolocumab, including the absence of Phase III bioequivalence data for the compounded version

No randomized controlled trial has evaluated compounded evolocumab specifically. The 59% LDL-C reduction and cardiovascular outcomes data from FOURIER apply to the FDA-approved Amgen formulation only. [3]

Can You Get a Repatha Prescription via Telehealth in Louisiana?

Telehealth prescribing of evolocumab is legal and accepted practice in Louisiana as of 2026. Louisiana law permits controlled substance prescribing via telehealth under specific conditions, but evolocumab is not a controlled substance, so the standard telehealth prescribing rules apply. [13]

Louisiana's telehealth statute (La. R.S. 40:1223.3) requires that a valid patient-provider relationship exist before prescribing via synchronous video or audio-video visit. [13] A Louisiana-licensed prescriber, including physicians, nurse practitioners, and physician assistants with prescriptive authority, may evaluate a patient, review lipid panel results, assess cardiovascular risk, and issue a Repatha prescription through a telehealth platform.

For Louisiana patients, this means:

• A recent lipid panel (within 3-6 months) is required before prescribing
• The prescriber must review prior statin therapy and intolerance history
• Insurance prior authorization paperwork can be submitted by the telehealth provider
• Follow-up LDL-C testing at 4-8 weeks post-initiation confirms response

HealthRX physicians licensed in Louisiana routinely manage PCSK9 inhibitor therapy through telehealth visits. Patients with a prior ASCVD event or a confirmed FH diagnosis typically qualify for same-day prescription issuance after chart review. The ACC/AHA 2022 guidelines recommend initiating PCSK9 inhibitor therapy in very-high-risk ASCVD patients with LDL-C at or above 70 mg/dL on maximally tolerated statin therapy, and this guideline applies regardless of whether the visit occurs in-person or via telehealth. [6]

What Is the Cheapest Way to Get Repatha in Louisiana?

The lowest-cost pathway depends entirely on your insurance status. Here is a direct comparison for Louisiana patients in 2026:

Commercially insured patients: Use the Amgen copay card. Out-of-pocket cost can reach $0 per month for patients whose plans have formulary coverage. The card covers up to $3,600 per year. [9]

Medicare Part D enrollees: GoodRx coupons do not stack with Medicare. The lowest-cost route is confirming your plan's formulary, requesting tier exception if evolocumab is not covered, and applying for the Amgen Safety Net Foundation if your income qualifies. Mark Cuban's Cost Plus Drugs does not currently carry biologics including evolocumab, so that option is not available.

Louisiana Medicaid enrollees: Brand Repatha is not covered. Appeal through your MCO with physician documentation. If denied, compounded evolocumab through a licensed 503A pharmacy with a documented clinical rationale may be the only accessible option. Some patients also qualify for the Amgen Safety Net Foundation. [10]

Uninsured patients: The Amgen Safety Net Foundation provides free Repatha to qualifying patients earning up to 500% FPL. Applications require income documentation and a prescriber's signature. Processing typically takes 2-4 weeks. [10]

Patients seeking the fastest cost reduction: A licensed 503A compounding pharmacy in Louisiana may offer evolocumab at substantially below list price. Confirm USP <797> compliance before dispensing. The clinical evidence supporting the compounded version's efficacy is limited to extrapolation from the FOURIER trial data on the FDA-approved product. [3]

Understanding Evolocumab's Clinical Evidence Basis

FOURIER remains the landmark outcomes trial for evolocumab. Published in the New England Journal of Medicine in 2017, the trial enrolled 27,564 patients with established ASCVD who were on optimized statin therapy. [3] Patients received evolocumab 140 mg every 2 weeks or 420 mg once monthly versus placebo. At a median follow-up of 2.2 years, LDL-C fell from a median of 92 mg/dL at baseline to 30 mg/dL in the evolocumab group, a 59% reduction. [3]

The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of evolocumab-treated patients versus 11.3% of placebo-treated patients (HR 0.85, P<0.001). [3] The key secondary endpoint of cardiovascular death, MI, or stroke occurred in 5.9% versus 7.4% (HR 0.80, P<0.001). [3]

A secondary analysis of FOURIER published in the Journal of the American College of Cardiology showed that patients who achieved LDL-C below 20 mg/dL had the lowest event rates, with no safety signal for neurocognitive or other adverse events at that level of LDL-C reduction. [14]

For patients with familial hypercholesterolemia, the RUTHERFORD-2 trial (N=329) showed that evolocumab 140 mg every 2 weeks reduced LDL-C by 59.2% versus placebo at 12 weeks (P<0.001). [15] The 2023 European Atherosclerosis Society consensus statement on FH recommends PCSK9 inhibitors as the preferred third-line agent after statin plus ezetimibe when LDL-C targets are not reached. [16]

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease does not recommend PCSK9 inhibitors as first-line therapy but acknowledges their role in secondary prevention and FH management: "In patients with LDL-C levels persistently ≥70 mg/dL, it is reasonable to add a PCSK9 inhibitor to maximally tolerated statin and ezetimibe therapy." [17]

How to Start Repatha Therapy in Louisiana: A Step-by-Step Overview

Starting evolocumab in Louisiana requires a valid prescription, a confirmed clinical indication, and a clear plan for insurance or cost coverage. The clinical steps follow naturally from the ACC/AHA guidelines.

Step 1: Confirm the indication. Get a fasting lipid panel. If LDL-C remains at or above 70 mg/dL (for ASCVD) or 100 mg/dL (for primary prevention with FH) despite maximally tolerated statin therapy, you meet the threshold for considering a PCSK9 inhibitor. [6]

Step 2: Add ezetimibe first if not already prescribed. Most commercial insurance plans and the ACC/AHA guidelines recommend a trial of ezetimibe 10 mg daily before escalating to a PCSK9 inhibitor. Ezetimibe costs under $10/month at most Louisiana pharmacies with a GoodRx coupon and reduces LDL-C by an additional 18-20% on average. [18]

Step 3: Document the clinical case. Your prescriber should document your LDL-C history, statin doses tried, intolerance notes, and ASCVD or FH diagnosis. This documentation forms the prior authorization submission.

Step 4: Choose a pharmacy. Retail pharmacies including CVS, Walgreens, and Walmart in Louisiana can fill Repatha with a standard prescription. Some plans require specialty pharmacy dispensing through Accredo or CVS Specialty.

Step 5: Apply for the Amgen copay card. Do this before filling the first prescription. The card can be activated within minutes online at repatha.com. [9]

Step 6: Schedule a follow-up. Recheck LDL-C at 4-8 weeks after the first injection. The ACC/AHA recommends a target LDL-C below 70 mg/dL in very-high-risk ASCVD patients. [6] Evolocumab reaches near-maximal LDL-C reduction within 4 weeks of starting therapy. [3]

Patients starting evolocumab in Louisiana through a HealthRX telehealth visit can have their prior authorization paperwork submitted on the same day as the visit. Commercially insured patients in Louisiana who apply the Amgen copay card before their first fill should expect a $0 copay at most in-network pharmacies for the first fill.